Generic Embeda Availability
Last updated on May 7, 2025.
Embeda is a brand name of morphine/naltrexone, approved by the FDA in the following formulation(s):
EMBEDA (morphine sulfate; naltrexone hydrochloride - capsule, extended release;oral)
-
Manufacturer: ALPHARMA PHARMS
Approval date: August 13, 2009
Strength(s): 20MG;0.8MG (discontinued) [RLD], 30MG;1.2MG (discontinued) [RLD], 50MG;2MG (discontinued) [RLD], 60MG;2.4MG (discontinued) [RLD], 80MG;3.2MG (discontinued) [RLD], 100MG;4MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Embeda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical composition
Patent 7,682,633
Issued: March 23, 2010
Inventor(s): Matthews; Frank et al.
Assignee(s): Alpharma Pharmaceuticals, LLC (Bridgewater, NJ)Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
Patent expiration dates:
- June 19, 2027✓
- June 19, 2027
-
Pharmaceutical compositions
Patent 7,682,634
Issued: March 23, 2010
Inventor(s): Matthews; Frank et al.
Assignee(s): Alpharma Pharmaceuticals, LLC (Bridgewater, NJ)Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
Patent expiration dates:
- June 19, 2027✓
- June 19, 2027
-
Sequestering subunit and related compositions and methods
Patent 7,815,934
Issued: October 19, 2010
Inventor(s): Boehm; Garth
Assignee(s): Alpharma Pharmaceuticals, LLC (Bridgewater, NJ)A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit and a therapeutic agent in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
Patent expiration dates:
- December 12, 2027✓
- December 12, 2027
-
Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
Patent 8,158,156
Issued: April 17, 2012
Inventor(s): Matthews Frank & Boehm Garth & Tang Lijuan & Liang Alfred
Assignee(s): Alpharma Pharmaceuticals, LLCProvided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
Patent expiration dates:
- June 19, 2027✓
- June 19, 2027
-
Pharmaceutical composition
Patent 8,623,418
Issued: January 7, 2014
Inventor(s): Liang Alfred & Matthews Frank & Boehm Garth & Tang Lijuan & Johnson Frank & Stauffer Joseph
Assignee(s): Alpharma Pharmaceuticals LLCProvided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.
Patent expiration dates:
- November 7, 2029✓
- November 7, 2029
-
Sequestering subunit and related compositions and methods
Patent 8,685,443
Issued: April 1, 2014
Inventor(s): Boehm Garth
Assignee(s): Alpharma Pharmaceuticals LLCA sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
Patent expiration dates:
- July 3, 2025✓
- July 3, 2025
-
Sequestering subunit and related compositions and methods
Patent 8,685,444
Issued: April 1, 2014
Inventor(s): Boehm Garth
Assignee(s): Alpharma Pharmaceuticals LLCA sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
Patent expiration dates:
- July 3, 2025✓
- July 3, 2025
-
Pharmaceutical compositions for the deterrence and/or prevention of abuse
Patent 8,846,104
Issued: September 30, 2014
Inventor(s): Matthews Frank & Boehm Garth & Tang Lijuan & Liang Alfred
Assignee(s): Alpharma Pharmaceuticals LLCProvided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
Patent expiration dates:
- June 19, 2027✓
- June 19, 2027
-
Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
Patent 8,877,247
Issued: November 4, 2014
Inventor(s): Matthews Frank & Boehm Garth & Tang Lijuan & Liang Alfred
Assignee(s): Alpharma Pharmaceuticals LLCProvided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
Patent expiration dates:
- June 19, 2027✓
- June 19, 2027
More about Embeda (morphine / naltrexone)
- Embeda consumer information
- Check interactions
- Compare alternatives
- Reviews (47)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: narcotic analgesic combinations
Related treatment guides
Related/similar drugs
Paracetamol
Paracetamol (Panadol, Calpol, Alvedon) is a widely used over-the-counter painkiller and fever ...
Tylenol
Tylenol is a pain reliever and a fever reducer used to treat many conditions such as headaches ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Cymbalta
Cymbalta (duloxetine) is used to treat major depressive disorder, general anxiety disorder and ...
Oxycodone
Oxycodone is an opioid analgesic used to treat moderate to severe pain; it has a high potential for ...
Naproxen
Naproxen is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation caused by ...
Amitriptyline
Amitriptyline is a tricyclic antidepressant used to treat depression and, off-label, conditions ...
Duloxetine
Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor antidepressant used to ...
Tramadol
Tramadol is an opioid medication that may be used to treat moderate to moderately severe chronic ...
Cyclobenzaprine
Cyclobenzaprine is a muscle relaxant and works by blocking pain sensations. Includes ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
